Harniess 01
Upcoming SlideShare
Loading in...5

Harniess 01






Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • Utube clip temporal epilepsy?
  • ?UTUBE clip Check for tremor Inspection of facial expression – loss of movement, lack of expression Gait – difficulty with initiation, shuffling stooped gait, loss of arm swing, difficulty turning around – moving around like a statue Cog wheel rigidity What are the positive signs diagnostic?? – check NICE guidelines
  • General rules on record keeping GMC guidance Verbal Scenario – written recording of clinical encounter – discuss with friend? SOAP acronym Positive and negative findings Show evidence of discriminatory (hypothetic-deductive) thinking Medicolegal back up Continuation of medical treatment – can a colleague follow up on this patient from your records? Examples of good and poor documentation ?MDU/MDDUS
  • Screening qu’s with chronic disease – would they bring it up example of cancer on oncology ward
  • Screening qu’s with chronic disease – would they bring it up example of cancer on oncology ward
  • A prospective study focusing on metabolic disturbances in patients with schizophrenia, including an oral glucose tolerance test indicated that metabolic abnormalities are already present in first-episode patients, and considerably increased with increasing duration of illness. When compared to the general population matched for age and gender, much higher rates of the metabolic syndrome (MetS) and diabetes were observed for patients with schizophrenia. For MetS, the increase over time was similar to that of the general population. In contrast, the difference in the prevalence of diabetes in patients with schizophrenia and the general population dramatically and linearly increased from 1.6% in the 15-25 age-band to 19.2% in the 55-65 age-band. The data suggest that on the one hand metabolic abnormalities are an inherent part of schizophrenic illness, as they are already present in first-episode patients. On the other hand, however, the results suggest a direct effect of the illness and/or antipsychotic medication on their occurrence. The data underscore the need for screening for metabolic abnormalities in patients diagnosed with schizophrenia, already starting from the onset of the illness.

Harniess 01 Harniess 01 Presentation Transcript